Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial

Nov 28, 2017

Table of Contents

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine

Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Migraine.

GSK to integrate Owlstone Medical’s Breath Biopsy Platform into their Clinical Trial

Owlstone Medical has announced that GSK will incorporate Owlstone Medical’s Breath Biopsy platform into their clinical development programme of Danirixin. It is a novel drug candidate in its respiratory disease pipeline.

Downloads

Article in PDF

Recent Articles

Notizia

FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmaca...

Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market

Amgen’s IMDELLTRA FDA Approval; J&J’s Proteologix Acquisition; Bristol Myers Squibb’s B...

PI3Kγ- a molecular switch that controls immune suppression

Teligent has recently got the First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%

Teligent a New Jersey-based specialty generic pharmaceutical company, has recently announced that it has received generic drug approval for the Company’s abbreviated new drug application from the FDA of Hydrocortisone Butyrate Lotion 0.1% used for treating various skin related disorders.

After positive results of new phase III trial results Catalyst is back with Firdapse for FDA approval

Catalyst Pharmaceuticals is back about 18 months after the FDA filtered out their lead drug Firdapse (amifampridine phosphate) again to the clinic with a demand for more clinical data. The drug is used for the treatment of patients suffering from LEMS (Lambert Eaton Myasthenic Syndrome).